Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Abstract: A shingle assembly that contains a fiber mat and an asphalt mixture disposed within the fiber mat. The asphalt mixture contains asphalt and a mineral filler; a layer of mineral granules is disposed on the top surface of the shingle assembly; the mineral granules contain at least about 40 weight percent of limestone particles that have a hardgrove grindability index of less than 70; and the particles are coated with an oil.

Abstract: A process for making a composition of asphalt and filler in which a viscosity reducing additive is sprayed onto particles of shingle filler material to produce coated shingle filler material, the coated shingle filler material is heated, asphalt is heated, and the heated coated shingle filler material is mixed with the heated asphalt.

Abstract: A composition comprised of asphalt and filler, wherein said filler is comprised of particles that comprise an inorganic core and a coating disposed on said core, and wherein at least about 60 weight percent of said particles are smaller than about 212 microns.